Phase 2 N=80 Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Tumor Pathway Activations Inhibited by Dovitinib
Primary: Clinical Benefit Rate (CBR) — 0; 1; 10; 11 number of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=191 B0151005 Open-Label Extension Study
Crohn's Disease
Primary: Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs — 171; 58; 54 participants
N/A N=110 Active Versus Passive Motion Device Following Knee Replacement Surgery
Knee Arthroplasty
Primary: Early Functional Outcome Strength — 12.02; 11.60 newton meter
Phase 3 N=264 Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Attention-Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Visit 6 (Week 4) — 40.0; 39.0; -11.7; -21.5 Units on a scale…
N/A N=32 The Oral Contraceptive Pill for Premenstrual Worsening of Depression
Premenstrual Syndrome · Depression
Primary: Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS) — -43.6; -38.9 percent change — p=.59
Phase 2 N=48 Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
N/A N=83 Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis · Vitamin D Deficiency
Primary: Disease Activity Score (DAS) 28 — 3.4; 2.8; 3.5; 3.1 composite score
N/A N=59 Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression
Antiretroviral Treatment Outcomes
Primary: The Antiretroviral Treatment Failure Rate at 12 Months. — 4; 5 participants — p=1.00
N/A N=265 Rheos® Pivotal Trial
Hypertension
Primary: Percent of Patients With a 10mmHg or Greater Reduction in Office Cuff Systolic Blood Pressure — 54.1; 46.4 percentage of participants
Phase 3 N=363 A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score (n=102, 104, 106) — -22.85; -23.70; -24.37 Score on a scale…
N/A N=79 Living Well With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04
Phase 1 N=47 A Study of LY2405319 in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 1; 0 number of…
N/A N=21 Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV
Periodic Breathing · Breathing-Related Sleep Disorder
Primary: Apnea/Hypopnea Index (AHI) — 3.9; 6.4 Events per hour — p=0.022
Phase 1 N=65 A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
Influenza
Primary: Steady-state Area Under the Plasma Concentration Versus Time Curve From Time Zero to 12 Hours of Oseltamivir and Oseltamivir Carboxylate — 277; 194; 142; 4990 hour…
Phase 3 N=402 A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A) — -0.54; 0.00 Percent — p=<0.001